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Increasing evidence points to vascular damage as an early contributor to the development of two leading causes of age-associated
dementia, namely Alzheimer disease (AD) and AD-like pathology such as stroke. This review focuses on the role of G protein-
coupled receptor kinases (GRKs) as they relate to dementia and how the cardio and cerebrovasculature is involved in AD
pathogenesis. The exploration of GRKs in AD pathogenesis may help bridge gaps in our understanding of the heart-brain
connection in relation to neurovisceral damage and vascular complications of AD. The a priori basis for this inquiry stems from
the fact that kinases of this family regulate numerous receptor functions in the brain, myocardium and elsewhere. The aim of this
reviewistodiscusstheﬁndingofGRK2overexpressioninthecontextofearlyADpathogenesis.Also,weconsidertheconsequences
for this overexpression as a loss of G-protein coupled receptor (GPCR) regulation, as well as suggest a potential role for GPCRs
and GRKs in a unifying theory of AD pathogenesis through the cerebrovasculature. Finally, we synthesize this newer information
in an attempt to put it into context with GRKs as regulators of cellular function, which makes these proteins potential diagnostic
and therapeutic targets for future pharmacological intervention.
Copyright © 2009 Mark E. Obrenovich et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
G protein-coupled receptor kinases (GRKs), such as GRK2,
are cytosolic proteins that contribute to the adaptation of the
heptahelicalGprotein-coupledreceptors(GPCRs)andtothe
regulation of their downstream signals. GPCRs mediate the
action of messengers that are key modulators of cardiac and
vascular cell function [1]. A family of seven mammalian ser-
ine/threonine protein GRKs have been identiﬁed. GRK2 and
3 form the second subfamily, namely, β-adrenergic receptor
kinase (βARK), whose members can phosphorylate and
regulateagonist-occupiedorconstitutivelyactiveGPCRs[2].
When recruited to the cell membrane, homology domains
of GRK2 modulate the simultaneous inhibition of signaling
by G-alpha, G-beta, and G-gamma subunits. Recent studies
suggest that GRKs, particularly GRK2, may have more
diverse protein/protein cellular interactions because of a
consensus caveolin binding motif within the pleckstrin
homology domain of GRK2 [3].
Normal aging and sporadic late-onset AD have many
features in common. AD-like symptoms only appear to
manifest when certain quantitative levels of damage occur
[4, 5]. This damage includes metabolic and oxidative stress,
as well as those factors associated with impaired cerebral
perfusion, which all are attributed to risk. Examples of
impaired perfusion include cardiovascular and cerebrovas-
cular diseases, hypo/hypertension, and stroke, which impair
the body’s ability to adequately cope with further insults2 Cardiovascular Psychiatry and Neurology
[5, 6]. We speculate that an imbalance in the activity of nitric
oxide synthase (NOS) isoforms, endothelin-1 (ET-1), and
oxidative stress, as evidenced by several biomarkers of this
damage, along with mitochondrial DNA (mtDNA) aberra-
tions and mitochondrial enzyme imbalance in vascular wall
cells and neurons, leads to inadequate antioxidant response
[4]. An adequate antioxidant reserve capacity is needed to
suﬃciently abate metabolic and oxidative insults, which are
twokeyinitialfeaturesinthebrainsofstrokeandADpatients
[7]. We further hypothesize that GRK2 plays a role in these
deleterious processes [8].
Under conditions associated with advanced aging, any
imbalance in the activity of NOS isoforms, ET-1, and
oxidative stress can lead to a potential and very destructive
positive feedback loop [9–11], in which increased levels of
reactive oxygen species (ROS) interfere with NO function,
lead to endothelial relaxation by reducing its bioavailability
(through ROS scavenging), increase the amount of oxidative
stress levels through the production of peroxynitrite, impair
endothelial barrier function, promote leukocyte adhesion,
and induce alterations in normal vascular function, which
further decreases cerebral blood ﬂow (CBF) [11]. It appears
that transient GRK2 activity correlates with compensatory
changes to oxidative stress and arterial occlusion, including
changes in endothelin-1 (ET-1) expression [4, 10]. Although
we are aware that correlation does not necessarily imply cau-
sation, we are equally cognizant of the axiom necessitating
correlation in order for causation to be supported. With this
in mind, we investigate what role GRK2 may play in the
early pathogenesis of dementia and determined the cellular,
subcellular, and ultrastructural distribution and localization
of GRK2 immunoreactivity in cases of human AD as well
as in a mammalian model of chronic brain hypoperfusion
(CBH), as ﬁrst seen with light microscopy and conﬁrmed by
western blotting [8].
Additionally, the involvement of CBH and physical dis-
tortion of the surrounding tissue exacerbate this imbalance
and more than likely contribute to the collapse of postis-
chemic/hypoxic vessels. Sustained hypoperfusion and oxida-
tive stress, both primary features of aged brain tissue during
theprodromalstagesofAD[6,12,13],alsomaystimulatethe
expression of various NOS species and subsequent ET-1 in
brain cells and probably increase the accumulation of oxida-
tive stress products, thereby contributing to blood-brain
barrier (BBB) breakdown, increased NO, and peroxynitrite
production and resulting in brain parenchymal cell damage
(for a more in-depth discussion regarding the interactions
of each of these factors please see our previous works [10,
14]). These ﬁndings raise questions regarding the direct
relationship between oxidative stress, energy failure (e.g.,
mitochondrial lesions) or metabolic insuﬃciency, neuronal
and vascular damage, BBB breakdown, and Aβ deposition
during the maturation of AD-like pathology [4, 10].
Increasing evidence for the roles of GRKs and
angiotensin 1 and 2 (AT1 and AT2) in hypertension,
stroke, and heart disease with association between these
receptors/ligands in heart disease and AD [15], as well as
early amyloid-β (Aβ) accumulation in vitro [16]a n do u r
in vivo work with models of hypoperfusion [8]p r o m p t s
further consideration of AD and AD-like pathology in
terms of possible inclusion and classiﬁcation as disorders
of the cerebrovasculature, because they involve common
receptor types. Our in vivo ﬁndings demonstrated the
early involvement of this kinase in both cerebrovascular
ischemia and AD [8]. During ischemic injury and in the
vulnerable neurons of AD patients, we found increased
GRK2 immunoreactivity. Therefore, cellular and subcellular
investigations into the mechanisms preceding Aβ deposition
and progression, as well as the possible accelerating eﬀects of
environmental factors such as chronic hypoxia/reperfusion,
were crucial to understanding of events that precede
amyloid deposition and which may lead to insights into new
pharmacological treatments of AD [8, 17].
2. GeneralFeaturesof GRKs
GRK function and interaction are complicated and its
importance compels increasing research interest. GRKs
function to regulate receptor traﬃcking of GPCRs and,
thus,dictatetheappropriatesignalmagnitudeandspeciﬁcity
for the downstream signal events from diverse extracel-
lular stimuli, controlling a vast number of physiological
processes. GRKs regulate numerous receptor functions in
both the brain and myocardium [18] and its actions are
more functionally diverse than previously thought. General
features of GRK interaction with GPCRs involve complex
regulatory mechanisms that modulate receptor responsive-
ness and underlie signal integration and desensitization
[19]. GRKs are members of a multigene family, which are
classiﬁed into three subfamilies. GRK2 and 3 form the
second subfamily (beta-adrenergic receptor kinase (beta-
ARK)subfamily),whichphosphorylateandregulateagonist-
occupied or constitutively active GPCRs. BetaARK1 (also
knownasGRK2)isthemostabundantGRKintheheart,and
it is increased in several cardiovascular diseases associated
withimpairedcardiacsignalingandfunction,suggestingthat
this protein could have pathophysiological relevance in the
setting of heart failure.
GRKs phosphorylate PAK, MEKK/Raf, MEK, MAPK,
SAP/JNK, p38, Arrestins, beta2-adrenergic receptor, and
other proteins. GRKs phosphorylate and recruit beta-
arrestin to the receptors in order to attenuate receptor desen-
sitization and initiate internalization of G protein-coupled
receptors by phosphorylating serine and threonine residues
and trigger arrestin binding, which can then be sorted to
endosomes and lysosomes. Further, covalent modiﬁcation of
GPCRs with ubiquitin serves as a signal for internalization as
well. Failures in ubiquitin-mediated proteolysis may explain
the accumulation of GRKs in AD and hypoperfusion, where
posttranslational modiﬁcation of critical lysine residues may
impair proteolysis. Many receptors for neurotransmitters
and hormones rely upon members of the Gq-alpha family of
heterotrimericGproteinsbecausetheydirectlylinkreceptors
totheactivationofPLC-betaisoforms,which,inturn,stimu-
late inositol lipid, calcium, and PKC signaling. Hubbard and
Hepler demonstrated that Gq-alpha, G11-alpha, G14-alpha,
and G15/16-alpha regulate both overlapping and distinctCardiovascular Psychiatry and Neurology 3
signaling pathways independent of inositol lipid signaling,
while also showing the inhibition of Gq-alpha-dependent
PLC-beta1 activity by PKG and PKA when mediated by
stimulatory phosphorylation of RGS4 and GRK2 [20].
GRKs critically regulate beta-arrestin signaling via recep-
tor phosphorylation and the triggering of desensitization.
The beta-arrestins play a crucial role in regulating the
responsiveness of multiple GPCRs [19]. The molecular
mechanisms of desensitization are quite complex and have
been investigated largely with the beta2-adrenergic receptor
(beta2AR) used as the main model system. Recent data from
Mayor and colleagues indicate that, besides the uncoupling
function, GRK2 and beta-arrestin also directly participate
in beta2AR sequestration, thus providing the trigger for its
resensitization. This is followed by binding of uncoupling
proteins (arrestins) and transient receptor internalization,
which plays a key role in resensitizing GPCR by allowing its
dephosphorylation and recycling [19]. A detailed knowledge
of the role of GRKs and arrestins in betaAR internalization
would make their physiologic role in the modulation of
cellular responses to messengers better understood and is
much too complex to address in this review. It has been
shown that stimulated β1-AR can recruit GRK to the
membrane. Either β-AR subtype’s interaction with GRKs
is via the intracellular loops and at the c-terminus of the
receptors.
Recent work has revealed potential phosphorylation-
independent regulation of GPCRs by GRK2 and GRK3 [21].
Further, GRKs themselves may be regulated by caveolin [3].
Nevertheless, reduced expression of GRK and beta-arrestins
leads to supersensitization of GPCRs and increases the
response to neuropeptides, neurotransmitters, chemokines,
and many other molecules. Thus, overexpression of these
GRKs could serve as a protective or compensatory response
to these stressors and chronic stress conditions involving
excitotoxicity. Further, GRKs together with A-kinase anchor-
ing proteins (AKAPs) assemble several cAMP eﬀectors,
including target protein kinase A (PKA) for cAMP signaling
to the cytoplasmic surface of mitochondria, and stimulate
PKA-dependent phosphorylation of the proapoptotic pro-
tein BAD, which inhibits release of cytochrome c from
mitochondria, and protect cells from apoptosis [22].
3. ExpressionandLocalization of GRKs
The various GRK subtypes diﬀer in their localization, regu-
lation, and mode of action. Many GRKs are highly expressed
in the heart, brain, and other tissues as shown in the rat
and hamster [23], where they regulate numerous receptor
functionsinthebrainandmyocardium[24].Desensitization
and resensitization of a wide variety of GPCRs are processes
involved in numerous brain functions and GRK2 expression
is increased in the developing rat brain, which is consistent
with an involvement in brain maturation processes [25]. The
expression in the developing brain and in AD is another
hallmark of AD, which is characterized by ectopic expression
of a multitude of cell cycle markers and proteins that are
involved in cell division and development, which we propose
as being an apparent recapitulation of ontogeny in this
disease [26]. These same analogies have been considered
in the parallels observed between AD and cancer and we
propose that they are examples of embryological parallelism
in both diseases [27]. In the rat brain, mRNA expression
pattern of GRKs family of proteins (GRK2, GRK3, GRK4,
and GRK6) was widely distributed and had nearly the same
expression pattern, although GRK3 generally was expressed
m o r ew e a k l yt h a nG R K 2i nm o s tt i s s u e s .
GRK2 has been well characterized in the heart, where
the onset of congestive heart failure (CHF) is associated with
characteristicchangesinmyocardialexpressionofGRK2and
is known to signiﬁcantly contribute to myocardial regulation
and function in the failing heart [28]. Signaling through car-
diac β-adrenergic receptors (βARs) is signiﬁcantly impaired
in many cardiovascular disorders, including CHF. Chronic
heart failure leads to upregulation of GRK2, both in cardiac
myocytes and in adrenal chromaﬃn cells, which results in
increased phosphorylation and desensitization of betaARs.
Further, elevated levels of GRK2 mRNA and GRK2 activity
have been reported in human left ventricle explants from
heart failure patients [29]. In the heart, βARs control numer-
ous trophic responses to the catecholamine neurotransmit-
ters, norepinephrine, and epinephrine. Heart failure onset is
characterizedbyreducedresponsivenesstoβ-adrenoreceptor
in cardiac tissues [30] and by changes in the expression of
GRK2 or β-adrenoreceptor kinase1 (bARK1) and signaling
of these receptors through the Gs protein-AC-PKA signaling
pathway [31]. When β-adrenoreceptor responsiveness was
examined in a completely developed reperfused myocardial
infarction model, higher levels of tissue catecholamines and
GRK2 were observed in the ischemic epicardium, leading
to sympathetic overstimulation of the failing heart [32].
It was found that the density of the β-adrenoreceptor in
the viable ischemic regions can be modiﬁed by GRK2 and
catecholamines. Conversely, cardiopulmonary intervention
was found to decrease GRK expression [33]. In chronic
heart failure, the adrenal chromaﬃn cell results in increased
GRK2 levels, which in turn results in increased phospho-
rylation and desensitization of alpha2ARs and subsequent
increased catecholamine secretion and, thus, circulating
catecholamines. The exposure to high levels of circulating
catecholamines has been reported to be toxic to cardiac
myocytes [34, 35]a n dp e r h a p sm a ya d v e r s e l ya ﬀect the
brain as well. Simultaneous inhibition of GRK2 in the
heart, the adrenal gland, and brain with an appropriate
pharmacological inhibitor may have a positive use in treating
chronic heart failure and perhaps AD.
G protein-coupled receptor desensitization is emerging
as an important feature of several cardiovascular diseases.
G R K 2p l a y sak e yr o l ei nt h er e g u l a t i o no fav a r i e t yo f
these receptors and cardiac muscle expression is altered
in pathological situations at the promoter level such as
in CHF [36], portal hypertension [37], and other tissues
and cells, such as lymphocytes [38] in these conditions.
GRK-dependent receptor desensitization and regulation of
βAR or other GPCRs is a rapid process that appears
to involve agonist-promoted receptor phosphorylation by
GRKs. GRK-mediated receptor phosphorylation promotes4 Cardiovascular Psychiatry and Neurology
the binding of arrestin proteins, such as β-arrestin [39].
β-arrestin binding uncouples G protein-coupled receptors
from their respective G proteins by sterically blocking
receptor coupling to G proteins. These same regulatory
proteins also modulate GPCR endocytosis and the processes
of transient receptor internalization, intracellular traﬃcking,
and resensitization [40]. Further, the internalization process
leads to ERK activation, as is the case for beta2AR and
lysophosphatidic acid receptor [41] and ERK activation,
known as a prominent feature of AD. Consequently, the β-
arrestins play a crucial role in regulating the responsiveness
of many GPCRs. GRK2, along with β-arrestin, plays a
key role in resensitizing GPCRs by allowing its dephos-
phorylation and recycling. Data by Mayor and colleagues
indicate that besides the uncoupling function of β-arrestin,
which together with GRK, directly participates in beta2AR
sequestrationandmayprovideone trigger forresensitization
[19]. GRK2 levels in myocardium and lymphocytes may
be associated with β-AR dysfunction and heart failure
severity.
Signaling through cardiac betaARs is signiﬁcantly
impaired in many cardiovascular disorders, including CHF.
Recent studies in several diﬀerent mouse models have
demonstrated that betaARK1 plays a key role not only
in the regulation of myocardial signaling, but also in
cardiac function and development [24]. Moreover, studies
have shown that targeting the activity of GRKs, especially
betaARK1, appears to be a novel therapeutic strategy for
the treatment of the failing heart. The development of small
molecule inhibitors of betaARK1 and GRK activity may
advance therapeutic options for heart disease [42], which
may be useful for AD as well, perhaps under conditions
where excitotoxicity is evident.
4.GRK,ET-1,and InsulinSignaling
Diabetes and Alzheimer’s disease have merged as a comor-
bidity factors and failures of energy homeostasis are involved
in both of disease processes, as diabetic individuals have
a 30- to 65-percent higher risk of developing Alzheimer
diseasecomparedtonondiabeticindividuals[43,44].Hyper-
glycemia increases DAG activates PKC-β and -δ, which can
decrease eNOS, increase ET-1, and eﬀect blood ﬂow. It
also activates VEGF, which aﬀects vascular permeability,
angiogenesis,andNADPHoxidases,whichincreaseoxidative
stress. GRK2 receptor is regulating signaling at the G protein
level by interacting with Gαq, Gα11, and Gα14, but not
Gαs, Gαi, Gα12/13, or Gα16 [45, 46]. The phosphorylation-
independent binding of the N-terminal domain of GRK2
to Gαq/11 can attenuate Gαq/11-mediated receptor signal-
ing of angiotensin II, endothelin receptor, thromboxane
A2 receptor, thyrotropin receptors, and mGluR1a/5. This
process depends on the GRK2 RGS homology domain [47,
48]. Importantly, direct activation of AMP-activated protein
kinase stimulates nitric-oxide synthesis in human aor-
tic endothelial cells. Phosphoinositide 3-kinase-dependent
activation of the 5 -AMP-activated kinase (AMPK) has
been demonstrated through peroxynitrite- (ONOO-) and
hypoxia-reoxygenation in cultured endothelial cells. Expo-
sure of aortic endothelial cells to ONOO- increased the
phosphorylation of AMPK and its downstream enzyme
endothelial nitric-oxide synthase and is accompanied by
increasedphosphorylationofproteinkinaseCzeta(PKCzeta)
[49].
In regard to energy metabolism and homeostasis, Gαs
can activate adenylyl cyclases, converting ATP into cAMP
and initiating PKA activation [50, 51]. Conversely, adenylyl
cyclases are inhibited by Gαi and the Gαq subunits that
activate phospholipase C (PLC)β, which hydrolyses phos-
phoinositol phosphate (PIP2) into diacylglycerol (DAG) and
inositol 1,4,5-trisphosphate (IP3), which then activate PKC
and the release of intracellular calcium. Adiponectin and its
receptorsareintegralplayersinmechanismsofenergyhome-
ostasis, which stimulate glucose utilization and fatty-acid
oxidation by activating AMP-activated protein kinase [52],
which regulates energy homeostasis and glucose and lipid
metabolism in adipocytes found in the brain. Adiponectin
is relevant, because it and its receptors have recently been
localized in the human pituitary gland, hypothalamus and
other brain regions, and hormone producing cells, such as
FSH, GH, LH, TSH, and ACTH [53].
When GRK2 was overexpressed in vitro, binding to PI3
kinase was found to promote PI3 kinase recruitment to
the plasma membrane, increasing receptor endocytosis [54].
PI3 kinases, with catalytic and regulatory subunits, generate
lipid products, which activate Akt. Class IB of PI3 kinases
sole member (PI3 kinase-γ) is composed of the regulatory
p101 subunit and the catalytic p110γ subunit. Upon GPCR
stimulation, Gβγ subunits directly bind to p110γ in the
activation of PI3 kinase-γ [55]. In addition, activated Gβγ
subunits control the activation of several eﬀectors, including
K+ channels, small G proteins, phosphoinositide-3 kinases
(PI3 kinases), and PLCβ [56].
GRK2 interacts with components of the PI3 kinase-
Akt and MAPK signaling cascades with consequences for
receptor signaling and desensitization. It has also been
reported that an interaction between GRK2 and Akt inhibits
the kinase activity of Akt in sinusoidal endothelial cells
from portal hypertensive rats [37]. PKC, PKA, and PLCβ
can mediate upstream activation of MAPKKK by G protein
interaction. The MAPK cascades are MAPK kinase (MAP-
KKK), which phosphorylates and activates a MAPK kinase
(MAPKK) and, in turn, activates one of the MAPKs, whose
members are ERK1/2, JNK1-3, p38MAPKα/β/γ, and the
more recently identiﬁed ERK5 [57].AllGαandGβγsubunits
have been described to trigger activation of the diﬀerent
MAPK pathways, with some Gα subunits exerting inhibitory
eﬀects on MAPKs [58, 59]. For example, phosphorylation
of p38MAPK by GRK2 uncovers a novel mechanism of
inhibition of the association of p38 with some of its partners
[60].
Sincewehavehypothesized theexistenceofanimbalance
between the NOS species and ET-1, we now suggest a
putative role of GRK2 in chronic ET-1-induced insulin
resistance in the brain and vascular wall cells, as it has been
found for other cells and tissues, which also may contribute
to consequences for Alzheimer and stroke patients by similarCardiovascular Psychiatry and Neurology 5
mechanisms. In that regard, GRKs, which are classical
serine/threonine kinases that desensitize agonist-occupied
GPCRs, have been found to regulate other receptors such as
the insulin receptor (IR), which is a tyrosine kinase receptor.
GRK2 was found to negatively regulate glycogen synthesis
in mouse liver FL83B cells [61]. This group demonstrated
that the IR also couples to G proteins, speciﬁcally GRK2,
and utilizes downstream signaling components to negatively
regulate IR signaling in those cells. In other tissues and cells,
GRK2 can function as a negative regulator of insulin action
by interfering with G protein-q/11 alpha-subunit (Gαq/11)
signaling [47], causing decreased glucose transporter 4
(GLUT4) translocation [48]. This same group reported that
chronic endothelin-1 (ET-1) treatment leads to heterologous
desensitization of insulin signaling with decreased tyrosine
phosphorylation of insulin receptor substrate (IRS)-1 and
Gαq/11 and decreased insulin-stimulated glucose transport
in3T3-L1adipocytes.ItisGRK2whichmediatesendothelin-
1-induced insulin resistance via the inhibition of both
Gαq/11 and insulin receptor substrate-1 pathways in these
cells. Another mechanism is one where GRK2 functions
as a negative regulator of insulin action through cdc42-
associated phosphatidylinositol 3-kinase activity and the
phosphorylation of IRS-1 and IRS-1 protein degradation.
Taken together, the importance of GRK2 in AD, vascular
dementia, and other metabolic diseases, such as diabetes,
shouldnotbeunderestimated.GRK2deﬁciencywasfoundto
increase the basal and insulin-stimulated phosphorylation of
Ser(21) in glycogen synthase kinase-3alpha. Insulin-induced
tyrosinephosphorylationoftheIRwassimilarincontroland
GRK2-deﬁcient cells [61]. Of interest here is the ﬁnding that
GRK2 mediates endothelin-1-induced insulin resistance via
theinhibitionofbothGαq/11andinsulinreceptorsubstrate-
1p a t h w a y si n3 T 3 - L 1a d i p o c y t e s[ 48]. Further, the same
group showed that chronic endothelin-1 (ET-1) treatment
leads to heterologous desensitization of insulin signaling
with decreased tyrosine phosphorylation of insulin receptor
substrate (IRS)-1 and Galphaq/11 and decreased insulin-
stimulated glucose transport in 3T3-L1 adipocytes. In the
current study, we have investigated the role of GRK2 in
chronic ET-1-induced insulin resistance.
Recent data suggest possible alternate roles for GRK2
other than as a kinase. In that regard, the role of phospho-
rylation of the endothelin B receptor (ETBR) in agonist-
induced desensitization was investigated, using mutant lack-
ing c-terminal 40 amino acids (delta 40 ETBR). In cells
expressingthewild-typeordelta40ETBR,ET-1causedrapid
desensitizationofcalciumresponses[62].Theseinvestigators
found that the wild type-ETBR was phosphorylated by
ET-1, and the phosphorylation was markedly enhanced
when coexpressed with GRK2. However, delta 40 ETBR
was not phosphorylated regardless of coexpression with
GRK2. Phosphatidylinositol 3 formation was ET-1 induced
in these cells and was decreased by coexpression with
GRK2 or kinase-dead GRK2 by a similar mechanism, by
which the authors suggest the presence of phosphorylation-
independent desensitization mechanism in delta 40 ETBR as
a possible alternate role for GRK2, other than those that are
kinase related in the strict sense.
Of importance in these GRK2 AD studies is the cellular
response to certain stimuli from the vascular endothelium,
neurons, and glia, which all are able to synthesize, store, and
release ROS, NO, and ET-1, a vasoactive peptide. In that
regard, elevated circulating glucose concentration leads to
many forms of pathology including increasing superoxide
formation that can form hydrogen peroxide, leading to
hydroxyl radical production, which can interact with NO to
form peroxynitrite. GRK2 is impaired by hydrogen peroxide
[63]. All of these reactive species can damage nucleic acids,
protein, and lipids, leading to oxidative stress through loss of
reducing equivalents, DNA strand breaks, poly(ADP)ribose
polymerase activation, and consumption of NAD+, which
ultimately impairs energy homeostasis. In support of this
notion, it is important to consider PARP activation in
diabetes, which is linked of increased oxidative stress and
leads to NAD+ depletion [64].
Their contribution to the pathophysiology of stroke or
stroke-like conditions and AD cannot be understated. ET-
1i sp r o d u c e db ym u l t i p l ec e l l sa n di sd i ﬀerentially coupled
to G proteins [45] in response to hypertrophic stimuli
in vitro and in the development of heart failure in vivo
[65, 66]. Nevertheless, the endothelin A and B receptors
(ETA-RandETB-R)undergodesensitization,mostlikelyalso
through GRK2 [67]. For example, ET-1 can elicit several
responses; it activates EC NOS via G protein beta/gamma
subunits signaling through protein kinase B/Akt [68]a s
well as prolonged physiologic responses, including mitogen-
activated protein kinase (MAPK) activation [69]a n dc -
Jun NH2-terminal kinase (JNK) and extracellular signal-
regulated kinase (ERK) in cultured animal cells and in
vivo [70]. MAP kinases have been long associated with
AD and ERK activation may be another important early
event, perhaps downstream from GRK2 activation [71].
Interestingly, these pathways also have been implicated in
cell-cycledysregulationinhumanADcases[72,73].Recently
we have demonstrated that since successful dysregulation of
the cell cycle is also the hallmark of a neoplastic changes,
earlycell-cyclepathophysiologyinADmayrecruitoncogenic
signal transductionmechanisms and, hence,couldbe viewed
as pseudoneoplastic transformation, which is eventually
aborted [74]. Further, it has been shown that phosphoryla-
tion of GRK2 by MAPK also triggers a turnover of GRK2
degradation through the proteasome pathway, in which
GRK2 is targeted for proteolysis by β-arrestin function and
Src-mediated phosphorylation [75]. Therefore, GRK2 may
play a very important role in AD pathogenesis mechanisms
through oxidative stress and mitochondrial dysfunction.
5.GRKStudiesinAD andCBH
Studies of the details and consequences of GRK’s
mechanisms have focused heavily on the original beta-
adrenoreceptor kinase (beta-ARK) family (GRK2 and
GRK3) and, in particular, on phosphorylation-dependent
recruitment of adaptor proteins such as the beta-arrestins.
Several lines of evidence implicate GRK and beta-arrestin
expression in AD and after cerebral hypoxia/ischemia (HI)6 Cardiovascular Psychiatry and Neurology
[18] and the diﬀerential GRK2 expression in compensated
hypertrophy and heart failure after myocardial infarction
in the rat. Moreover, G protein-coupled receptor kinases
regulate metabotropic glutamate receptor 5 function
and expression [76], which has also been implicated
in AD pathogenesis and GRKs may oﬀer a mechanism
for desensitization of this receptor isoform. The main
experimental goal of our previous study was to investigate
and better clarify the relationship between GRK2, vascular
lesions, and the development of pathology in a CBH model
and AD, at the cellular and subcellular levels [8]. In that
regard, we examined a connection between vascular damage
and predisposing factors for AD, where we explored the
changes in brain distribution of GRK2 in microvessel wall
cells and neurons using a CBH model and in AD cases. Our
previous studies and those of others have reported that CBH
will result in a 22%–30% reduction of hippocampal blood
ﬂow that will stabilize after several weeks without further
reduction [77–79]. This model is relevant to examining the
physiopathology of AD and stroke and enables exploration
of the relationship between vascular events and AD.
Our study was the ﬁrst where ultrastructural localization
demonstrated that the overexpression of GRK2 occurs dur-
ing the early stages of damage in aged human and AD cases
(see Figures 1 and 2), and also in our 2-VO model of CBH
(seeFigures3,4,and5).Thisoverexpressionisanearlyevent,
occurring at prodromal stages, before and up to a point
when the damage is reversible. Based on our observations,
we were able to detect the subcellular localization of GRK2
immunoreactivity in the neuronal cell body of the age-
matched control brain hippocampal tissues. We achieved
this by using preembedding immunogold decoration in the
hippocampus of age-matched control and AD rat brains.
These brains showed the presence of GRK2 containing gold
particles attached to the external membrane of partially
damaged mitochondria. In addition, GRK2 immunopositive
gold particles localized in the matrix of damaged mitochon-
dria and Golgi cistern. However these observations were
seen in the case when aged-matched damage occurred in
the hippocampal neurons. Contrary to this observation,
hippocampal tissue from the AD brain showed that the
neuronal cell body was characterized by the presence of large
number of mitochondria-derived lysosomes and disperse
distribution of GRK2 positive gold particles. Moreover, glial
cell body from the AD brain tissue also shows clusters of
GRK2 immunoreactivity in the matrix of mitochondria-
derived lysosomes (for the details see Figure 1). In our
AD and hypoperfusion studies, we observed less positive
signals for GRK in control cases, generally. Mostly GRK
positive gold label in electron microscopic studies was
observed bound to the residues of the diﬀerent cellular
compartments, such as damaged mitochondria, distorted
perivascular cells. Some positive signals were observed in
perivascular cells associated with damaged vessels as well as
in cellular compartments with lesions. Nevertheless, there
are pathological cellular structures, such as NFT-like and/or
vacuolar degenerative structures (GVD), which colocalized
with GRK2 [8]. In some cases GRK positive signals were










Figure 1: Subcellular localization of GRK2 immunoreactivity
detected by using preembedding immunogold decoration in hip-
pocampus of age-matched control (a, b) and AD brain (c, d). (a)
and (b) The neuronal cell body from the age-matched control brain
hippocampal tissue shows the presence of GRK2 containing gold
particles (arrows) attached to the external membrane of partially
damaged mitochondria. GRK2 immunopositive gold particles
localized in the matrix of damaged mitochondria and Golgi cistern,
X 30,000 and X 40,000, respectively, (a) and (b). (c) Hippocampal
tissue from the AD brain shows that the neuronal cell body is
characterized by the presence of large number of mitochondria-
derived lysosomes (M) and disperse distribution of GRK2 positive
gold particles (arrows), X 6,000. (d) Glial cell body from the
AD brain tissue shows clusters of GRK2 immunoreactivity in the
matrixofmitochondriaderived-lysosomes(singlearrow),X20,000.
Abbreviations: M Mitochondria; N cell nucleus, [reprinted with
permission of Neurotoxicity Research [8]
the ﬁrst known in vivo evidence demonstrating GRK2
activation in early cerebrovascular disease, including AD,
a n dt h u sG R K 2c o u l ds e r v ea san e wt a r g e tf o rt r e a t m e n t
approaches to AD, cerebrovascular dementia, or stroke [80].
Usually, GRK2 immunoreactivity was found to be
associated with damaged cellular compartments, especially
mitochondria and/or mitochondria-derived lysosomes or
granular/vacuolar degenerative structures (see Figures 1
and 2). The immunopositive reactivity was observed in
damaged vessel wall cells and their subcellular compart-








gold particles in postmortem human AD (a) and age-matched
control brain (b, c) tissues. (a) The GRK2: immunopositive
containing gold particles in the matrix of perivascular pericytes
(indicated by single thick arrows) but not in the cytoplasmic
matrix of severely damaged vascular endothelium (EC), X 40,000.
(b) and (c) The neurons close to perivascular regions show the
presence of GRK2 containing gold particles in their matrix, where
most gold particles were associated with the neuroﬁbrillary tangle-
(NFT-) like structures (arrows). However, the intact mitochondria
(M) were free from GRK2-immunopositive gold particles, X
40,000, respectively, (b) and (c). (reprinted with permission of
Neurotoxicity Research [8]).
that contain neuroﬁbrillary tangles (NFTs) show abundant
GRK2 immunopositive reactivity (Figure 2). The intensity
of the reaction varied from cell to cell and within cellular
compartments as well (Figures 1 and 2). However, cellular
lipofuscin was not associated with any GRK2 immunore-
activity. Nevertheless, there are pathological hallmarks of
AD present in harvested neurons, for example, neuronal
inclusions, or those neurons containing structures such as
NFTs, granular vacuolar degeneration (GVD), as well as
in microvascular wall cells, which show a highly intense












Figure 3: Ultrastructural characteristics of GRK2: immunopositive
gold particles from the rat brain in control (same-operated: a, b)
and 2-vessel occlusion (2-VO; resp., c, d) experiments. (a) Clusters
of GRK2: immunopositive gold particles in the cytoplasmic matrix
of perivascular pericytes (arrows) but not in the vascular EC, X
20,000. (b) The presence of GRK2 immunopositive gold particles
associated with the edematous portion of the perivascular pericytes
cytoplasmic matrix (arrows). Intact, but not giant, mitochondria
(M) are free from any GRK2-immunopositive positive gold par-
ticles, X 30,000. (c) The GRK2 containing positive gold particles
was seen in the hippocampal tissues from rat exposed to 2-VO.
The presence of GRK2 immunopositive gold particles was seen
throughout the matrix of damaged perivascular pericytes (arrows),
X 8,000. (d) Perivascular regions of this area from ﬁgure (c) under
higher magniﬁcation display the presence of islands of GRK2-
containing gold particles which are associates with the damaged
regions of the cytoplasmic matrix (arrows). Nucleus (N) and intact
mitochondria are from the GRK2 immunoreactivity, X 30,000.
(reprinted with permission of Neurotoxicity Research [8]).
scarce GRK2 immunorectivity in areas that were previously
abundant, suggest that overexpression of GRK2 can be lost
or reduced, which was conﬁrmed by western blotting [4].
Thus, this protein can serve as an earlier marker of the brain
damage that typiﬁes cerebral-vascular and/or mild cognitive
impairment, human AD, and damage in an animal model
that mimics AD. In addition, the overexpression of GRK2
immunoreactivity complements our earlier observation that
oxidativestress-induceddamageisobservedinmitochondria
and/or other cellular compartments before any amyloid












Figure 4: The subcellular features of the GRK2 immunoreactivity
in the hippocampus of the rat subjected to 2-vessel occlusion.
(a) Intact neurons show absence of any GRK2 immunopositive
gold particles in their cytoplasmic matrix, X 15,000. (b) Neurons
with the eﬀect of chronic cellular hypoperfusion demonstrate the
presence of a GRK2 overexpression (arrows) throughout the cell
body, however, the intact mitochondria (M) were free from any
GRK2 immunopositive gold particles, X 30,000. (c) “Hypoperfu-
sion”-aﬀected neuronal cell body show the presence of islands
of GRK2 positive immunodecoration in the external membrane
and in the matrix of damaged mitochondria and mitochondria-
derived lysosomal structures (arrows), X 40,000. (d) Neurons with
severe damage shows the presence of islands of GRK2 containing
immunopositive gold particles that associated with the completely
damaged (mitochondria-derived lysosomal structures) (arrows),
but not with nondamaged mitochondria (intact and giant), X
40,000. (reprinted with permission of Neurotoxicity Research [8]).
of GRK2 stability includes Mdm2 and the PI3K/Akt axis,
orchestrated in a stimulus, cell type, or context-speciﬁc
way, as well as the functional consequences of altering
GRK2 expression/functionality in speciﬁc cell types and
experimental models.
A parallel study reported abnormal GRKs in vitro
for early stages of AD, which is associated with early
amyloid beta (Aβ) accumulation in vitro and showed that
subthreshold Aβ pretreatment disrupts binding of GRKs
to activated GPCRs [16]. This led to reduced membrane
GRK2/5, which subsequently led to retarded GPCR








Figure 5: The GRK2 immunoreactivity in rat brain hippocampal
tissues was exposed to 2-vessel occlusion and determined by
using preembedding immunogold cytochemistry techniques. (a)
Subcellular determination of GRK2 in the neuronal cell body shows
the presence of GRK2 immunopositive gold particles (arrows),
which associates with the external membrane and the matrix
of damaged but not intact mitochondria (M), X 40,000. (b)
Neuronscontaininggranularvacuolardegenerativestructuresshow
island of GRK2 immunopositive gold particles (single arrow), X
30,000. (c) The glial cell body shows overexpression of GRK2
immunoreactivity in the matrix of granular vacuolar degenerative
structures (single arrow), X 50,000. (d) Neuroﬁlament from the
damaged neurons shows the presence of GRK2 immunopositive
gold particles (single arrows), X 40,000 (reprinted with permission
of Neurotoxicity Research [8]).
on to report in a transgenic mouse model of AD, where the
double-mutant form of APP695 is overexpressed under the
regulation of a prion promoter, the overexpression of GRK2,
and to a lesser extent GRK5, occurred in the cytosolic versus
membrane fractions from hippocampal and cortical brain
homogenates with increasing age and plaque deposition.
While the in vitro observation is quite likely to occur within
microglia, the increase in the overexpression of GRK2 and
GRK5 in the cytosol of neurons was not diﬀerentiated in this
study. Nevertheless, we report the subcellular localization
of GRK2 in neurons and the earlier involvement of vascular
lesions in vivo as a key event in this process and, thus, in the
development of human AD and AD-like pathology. Data toCardiovascular Psychiatry and Neurology 9
support this notion have been explored in various rat models
[77, 81]. In this regard, we have demonstrated that abnormal
mitochondria (mitochondria withelectrondensematrixand
mitochondrial-derived lysosomes) and lipofuscin appear to
be features of damaged hippocampal neurons in aged Tg
(+) mice and human AD, suggesting a direct relationship
between vascular abnormalities, BBB breakdown, neuronal
loss, and amyloid deposition [4, 10, 12, 14, 82].
Our in vivo data were discussed in light of another
study involving amyloid [16]; our model shows a similar
eﬀect, but attributes the overexpression of GRK2 to oxidative
stress and events prior to Aβ deposition. While the eﬀect
observed in the Sou study involved subthreshold levels of
the protein, which may reﬂect an early event as well, the
use of total homogenates from the transgenic model of Aβ
overexpression does not indicate which cells are aﬀected,
failingtocontrolforgliaorotherimmunologiccellsthatmay
be involved. However, since Aβ deposition is a later hallmark
lesioninAD,wesuspectthattheappearanceofAβalongwith
the loss of GRK2 immunoreactivity may be linked somehow,
but the role of Aβ on GRK2 translocation may be cell speciﬁc
and has not been characterized. Therefore, the appearance
of Aβ is unlikely to be the primary predisposing factor for
GRK2 overexpression, as Aβ deposition occurs much later
in the disease process. Any cytotoxicity may emanate from
mechanisms other than amyloid directly as earlier events
seem to be more crucial in the disease pathogenesis. Perhaps
early cytotoxicity resulting from non-amyloid-mediated
mechanisms may be more crucial in the etiopathology and
suggest that Aβ is less likely to be the primary predisposing
factor for GRK2 overexpression [12, 83].
Our studies demonstrate an increase in GRK2 localiza-
tion to the cytosol, but in particular to subcellular com-
ponents and only those components with damage and/or
pathology evident (see Figures 1–5). In our study we used
perfusion ﬁxation for the 2-VO model and for this reason
preservation of the tissue in 2-VO exposed animals was
much better than when compared to human postmortem
AD brain tissues, even after a very short postmortem time
period (<2–4 hours). However, in the general distribution
and the density of the GRK-2 containing gold particles, it
was very similar in the human AD and 2-VO animal models.
Recruitment of GRK to the cell membrane is followed
by inhibition of signaling. Therefore, the sequestration of
GRKs to subcellular locations may indicate a compensatory
adaptation to AD. However, other studies suggest that GRKs
have more diverse protein/protein cellular interactions and
that β-arrestins together with GRKs play a crucial role
in regulating the responsiveness of many GPCRs. Further,
GRK2 levels in myocardium and lymphocytes may be
associated with β-AR dysfunction as well, which is one
area that should be addressed in AD. One explanation for
the subsequent loss of GRK2 may lie in the ability of
Aβ to act as a bioﬂocculant [84] and a possible role in
the sequestration of GRK2, thereby limiting downstream
phosphorylation events as well, or leading to translocation
of GRK2 to the cytosol. Regardless, the reduced availability
of GRK2 and beta-arrestins to regulate GPRC signaling most
likely would lead to a state of GPCR supersensitization,
thereby increasing response to neuropeptides, neurotrans-
mitters, chemokines, and many other molecules; all of which
could have deleterious consequences. Conversely, it may be
plausible that increased GRK2 expression, and particularly
localization of an expression of modulation, and this would
impart a compensatory or survival response to excitotox-
icity, which is a claim made for Aβ as well [85]. Finally,
neurodegeneration can have numerous overlapping features,
and GRK2 along with the action of speciﬁc phosphatases
has been implicated in other neurodegenerative diseases
such as amyotrophic lateral sclerosis (ALS) [86]. Thus, there
are numerous parallels that can be drawn between the
neurodegenerative and cerebrovascular disorders with heart
disease and systemic vascular disorders, which drives home
the important connection the role GRK can have in all
disorders, particularly AD [87].
In comparison to controls, ultrastructure in AD and
animal models are predominated by abnormal mitochon-
dria. Studies examining deleted mtDNA and mitochondrial-
derived lysosomes in regions closely associated with lipofus-
cin suggest that proliferation, deletion, and duplication of
mtDNA occur in mitochondria in human AD and transgenic
mouse models of neurodegeneration [4, 10, 12, 14, 82].
In situ hybridization with a chimeric mouse and human
mitochondrial cDNA probes for the 5kb common deletion
indicate that the deletion is increased at least 3-fold in
AD cases as compared to controls and in yeast artiﬁcial
chromosome (YAC) APP mouse hippocampus [4, 10, 14,
88], which is strongly positively correlated (r = 0.934) with
the marker of DNA oxidation, 8-OH deoxyguanosine. These
ﬁndings indicate that the mitochondrial DNA overprolifera-
tion and/or deletion are key initiating factors for disruption
of the BBB and the development of pathology, and GRK2
immunoreactivity overexpression would be coincident with
these processes.
Earlier in a 2-VO model, we reported that ultrastruc-
tural examination of hippocampal CA1 capillaries in rats
revealed a smaller-size EC containing damaged mitochon-
dria,characterizedbytransformationoflysosomalstructures
within the EC and in the perivascular area [83]. Along
with mitochondrial abnormalities these changes appeared to
be associated with amyloid deposition found surrounding
the capillary vessel wall. Electron microscopic immunoas-
saying showed sparse endothelial-speciﬁc NOS- (eNOS-
) containing positive gold particles in the matrix of the
vascular endothelium, in contrast to substantial labeling in
the cytoplasmic matrix of perivascular cells and electron-
dense mitochondria, indicative of a hypoxic insult [83].
Immunoreactive eNOS-containing positive gold particles
were found markedly expressed in hippocampal neurons
and in glial cells, when compared to nonoccluded controls
[83]. Of interest is the comparison between the eNOS
overexpression pattern to that of GRK2 [37], which has the
same pattern as that of our previous observation of eNOS.
The EM ﬁndings in rat hippocampus after CBH also
support the general hypothesis that chronic oxidative stress
caused the EC structural changes and the mitochondrial
and immunoreactive eNOS changes, since such changes were
observed only in 2-VO rats. In addition, previously we have10 Cardiovascular Psychiatry and Neurology
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Figure 6: The role of GRK2 in AD showing the activation pathways and consequences of increased expression of GRK2 with the
endothelium, brain, and mitochondria.
demonstrated that oxidative damage is the earlier event in
AD [89]. These ﬁndings support our working hypothesis
that oxidative stress-induced vascular changes, such as an
abnormality in vascular NO, are important molecules in
spatial memory functions, at least in this CBH model.
Further, this damage coexists with overexpression of GRK2
immunoreactivity and in rats, hypoxia/ischemia modulated
GRK2, and beta-arrestin-1 levels [90].
Therefore, chronic oxidative stress-mediated inhibition
of eNOS may coexist with the early overexpression of
GRK2 immunoreactivity and would appear to support a
compensatory role or reaction in brain tissue to potentially
mitigate chronic injury stimuli such as oxygen depletion and
nutrient deﬁciency or imbalance in metabolic homeostasis
found in 2-VO conditions [83]. These data support the
present observation that it is chronic injury stimuli that not
only initiates damage and compensatory changes but also
accelerates brain damage in tissues, which can contribute
to some types of mental retardation and cognition deﬁcits
involving the consequence of Aβ accumulation in the
brain and in some types of mental retardation, such as
Down Syndrome [91]. The connection to a cerebrovascular
component to AD is further borne out in other rat studies,
where diﬀerentially expressed cardiac GRK2 expression and
activity have been found. Here, GRK2 expression has been
reported to be inhibited in animals with cardiac hypertrophy
without heart failure, whereas animals with heart failure had
elevated GRK2 [18]. The same can be said for failing human
hearts, which are reported to have elevated levels of GRK2
[92]. This expression pattern indicates diﬀerential regulation
in hypertrophic nonfailing and hypertrophic failing hearts.
Nevertheless, it is now a commonly held belief that GRKs
may likely become eﬀective therapeutic targets for heart
disease [42] and should be considered for AD or related
neuropathology as well (Figure 6).
6. Conclusions
Our growing understanding of GRK2 and its cognate
regulatory proteins provides support for a unifying hypoth-
esis of AD where these proteins play a pivotal role by
linking the many phenomenological observations into a
conceptual framework that contributes to a growing body
of evidence favoring the reclassiﬁcation of AD as, pri-
marily, a cerebrovascular disorder. For example, one clue
also may lie in the ﬁnding that GRK2 is a microtubule-
associated protein, and tubulin was identiﬁed as a novel
GRK2 substrate [93]. These results suggest that tubulin is
most likely phosphorylated in situ by GRK2 and that the
phosphorylation may aﬀect the interaction of microtubules
with microtubule-associated proteins (MAPs) [94]. Phos-
phorylation by GRKs may have downstream consequences
for neuronal cell death and perhaps contribute to the
hyperphosphorylated state of tau protein, as seen in AD orCardiovascular Psychiatry and Neurology 11
in earlier events as well, perhaps one that would predispose
to neuronal toxicity via NFT formation. However, recent
work has revealed potential phosphorylation-independent
regulationofGPCRsbyGRK2andGRK3[21]andGRK2was
not found to phosphorylate MAPs under conditions where
MAPs were already well phosphorylated by endogenous
kinases, which copuriﬁed with tubulin [95]. Nevertheless,
the role of this kinase in early phosphorylation of tau cannot
be discounted. Therefore, GRK2-mediated desensitization
may involve many diverse mechanisms. However, the role
of GRKs may be a pivotal one in AD pathology, as GRK-
mediated desensitization, in the absence of phosphorylation
and arrestin binding, has been reported for metabotropic
glutamate receptor 1 (mGluR1), the gamma-aminobutyric
acid B receptors [96], and in regulation of metabotropic
glutamate receptor 5 function and expression [97]. Both of
these receptors have been implicated in AD pathogenesis as
well [98, 99]. Therefore, GRKs may hold hope as therapeutic
targets for AD and related pathologies. Taken together, this
line of evidence strongly supports our ﬁndings of a role for
GRK2 as an earlier marker in AD pathogenesis and may
couple the contribution of oxidative stress, NO, eNOS, and
ET-1 to the pathobiology of AD (Figure 6).
Our ﬁndings also suggest a role for GRK2 as a GPCR
signal transducer, which may mediate the eﬀects of GPCR
activation on cytoskeletal structure and function in AD
[8]. Our study is the ﬁrst to demonstrate the cellular
and subcellular localizations and oﬀer in vivo evidence
for GRK2 activation as an early sign of cerebrovascular
aging complications in age-associated diseases involving
cerebrovascular abnormalities, neurodegeneration, and cog-
nitive impairment before any amyloid deposition can be
seen. GRKs as physiological regulators could become an
appropriate target for future pharmacological intervention.
Moreover, determining the mechanisms of the damage, or
potentialprotectivenatureofGRK2receptorantagonist,may
provide crucial information in the development of new and
more eﬀective therapies for stroke and AD patients. Further,
research in this direction may enable GRKs to serve as a new
target for treatment approaches to AD, stroke, mild cognitive
impairment, or related cerebrovascular disorders.
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